Pyxis Oncology, Inc. Retained Earnings
Pyxis Oncology, Inc. (PYXS) had Retained Earnings of -$491.80 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-13
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$491.80M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$466.45M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$443.18M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$425.07M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$491.80M 10-Q · filed 2026-08-13 |
| 2026-03-31 | -$466.45M 10-Q · filed 2026-05-14 |
| 2025-12-31 | -$443.18M 10-Q · filed 2026-08-13 |
| 2025-09-30 | -$425.07M 10-Q · filed 2025-11-03 |
| 2025-06-30 | -$403.07M 10-Q · filed 2025-08-14 |
| 2025-03-31 | -$384.71M 10-Q · filed 2025-05-15 |
| 2024-12-31 | -$363.56M 10-K · filed 2026-03-23 |
| 2024-09-30 | -$327.99M 10-Q · filed 2024-11-12 |
| 2024-06-30 | -$306.78M 10-Q · filed 2024-08-14 |
| 2024-03-31 | -$289.48M 10-Q · filed 2024-05-14 |
| 2023-12-31 | -$286.23M 10-K · filed 2025-03-18 |
| 2023-09-30 | -$270.63M 10-Q · filed 2023-11-07 |
| 2023-06-30 | -$247.58M 10-Q · filed 2023-08-11 |
| 2023-03-31 | -$231.68M 10-Q · filed 2023-05-11 |
| 2022-12-31 | -$212.44M 10-K · filed 2024-03-21 |
| 2022-09-30 | -$176.33M 10-Q · filed 2022-11-01 |
| 2022-06-30 | -$148.66M 10-Q · filed 2022-08-15 |
| 2022-03-31 | -$123.10M 10-Q · filed 2022-05-13 |
| 2021-12-31 | -$91.72M 10-K · filed 2023-03-22 |
| 2021-09-30 | -$74.89M 10-Q · filed 2021-11-15 |
| 2020-12-31 | -$15.74M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |